Women's Cancer Clinical Roundup
(AJMC Managed Markets Network) Nov 24, 2020 - Patients with epithelial ovarian cancer (EOC) who are treated with chemotherapy followed by prolonged poly-ADP-ribose polymerase inhibitors (PARP) may face a the possibility of a heightened risk of severe hematological toxicity, according to a new report.
(Medscape Medical News) Nov 23, 2020 - Women being treated for these cancers have less than ideal adherence to such medications, a new study has found – with just over half reporting taking them exactly as prescribed.
(ESMO Asia 2020) Nov 21, 2020 - The subgroup of East Asian women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer and disease progression on endocrine therapy participating in the phase III MONARCH 2 study continued to show improved survival outcomes compared to placebo plus fulvestrant at approximately 4-year...
(ESMO Asia 2020) Nov 21, 2020 - Pembrolizumab added to chemotherapy provided improved progression-free survival (PFS) in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) that were enrolled from Asia, investigators reported at the ESMO Asia Virtual Congress 2020, held from...
(WHO) Nov 17, 2020 - WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million related deaths by 2050.
(JAMA network open) - 2020-11-23
(ESMO open) - 2020-11-20
(JAMA Oncol) - 2020-11-19
(Clinical breast cancer) - 2020-11-13
(Int J Cancer) - 2020-11-16